Lifecome Biochemistry Co.,Ltd.

002868

CNE100002QH2

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 05/06/2024 am IST			5-day change	1st Jan Change
14.93 ^CNY	-2.55%		-10.17%	-29.77%

22/05	Lifecome Biochemistry Names Chairman	MT
29/04	Lifecome Biochemistry Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Shanghai Kanyi Proposes Temporary Review of "Proposal on Expected Guarantee Limit for Subsidiaries in 2023" at Company's Extraordinary Shareholders' Meeting

March 13, 2023 at 09:30 am IST

On March 13, 2023, the controlling shareholder, Shanghai Kanyi Investment Co., Ltd., proposed to submit the "Proposal on the Expected Guarantee Limit for Subsidiaries in 2023" as a temporary proposal for review at the company's 2023 second extraordinary shareholders' meeting.

Latest news about Lifecome Biochemistry Co.,Ltd.

Lifecome Biochemistry Names Chairman	22/05	MT
Lifecome Biochemistry Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Lifecome Biochemistry Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	29/04	CI
Lifecome Biochemistry Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	29/23/29	CI
Lifecome Biochemistry Co.,Ltd.(XSEC:002868) added to S&P Global BMI Index	18/23/18	CI
Lifecome Biochemistry Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/23/30	CI
Lifecome Biochemistry Co.,Ltd. announced that it expects to receive CNY 1.3 billion in funding	21/23/21	CI
Lifecome Biochemistry Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/23/28	CI
Lifecome Biochemistry Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	14/23/14	CI
Shanghai Kanyi Proposes Temporary Review of "Proposal on Expected Guarantee Limit for Subsidiaries in 2023" at Company's Extraordinary Shareholders' Meeting	13/23/13	CI
Lifecome Biochemistry Resumes Factory Operations	07/23/07	MT
Lifecome Biochemistry Co.,Ltd. completed the acquisition of Jiangxi Weike New Material Technology Co., Ltd. from Yushan County Wanghong Enterprise Management Center (Limited Partnership) and Wang Meijun.	30/23/30	CI
HOP LIK INVESTMENT COMPANY LIMITED, Fujie Investment Co., Ltd. and Zhejiang Kangmin Enterprise Management Co., Ltd. completed the acquisition of Fujian Putan Thermal Energy Co., Ltd. from Lifecome Biochemistry Co.,Ltd..	17/23/17	CI
HOP LIK INVESTMENT COMPANY LIMITED, Fujie Investment Co., Ltd. and Zhejiang Kangmin Enterprise Management Co., Ltd. agreed to acquire Fujian Putan Thermal Energy Co., Ltd. from Lifecome Biochemistry Co.,Ltd. for approximately CNY 300 million	08/22/08	CI
Lifecome Biochemistry Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	30/22/30	CI
Lifecome Biochemistry Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	30/22/30	CI
Lifecome Biochemistry Nixes Plan to Buy New Materials, Thermal Energy Firms	08/22/08	MT
A group of buyers singed a Cooperation Framework Agreement to acquire a 36.7% stake in Lifecome Biochemistry Co.,Ltd. from HOP LIK INVESTMENT COMPANY LIMITED, Fujie Investment Co., Ltd., and Beijing Kangmin Consulting Management Center (Limited Partnership) for approximately CNY 660 million.	01/22/01	CI
Lifecome Biochemistry Co.,Ltd. entered into framework agreement to acquire 100% Jiangxi Weike New Material Technology Co., Ltd. from Yushan County Wanghong Enterprise Management Center (Limited Partnership) and Wang Meijun for CNY 95 million.	01/22/01	CI
Lifecome Biochemistry Co.,Ltd. Approves Not to Pay Cash Dividend for 2021	20/22/20	CI
Lifecome Biochemistry Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	14/22/14	CI
Lifecome Biochemistry Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	11/22/11	CI
Zhongguancun Science-Tech to Buy, Lease Back Production Equipment of Veterinary Medicine	27/21/27	MT
Lifecome Biochemistry Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	28/21/28	CI
Lifecome Biochemistry Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	30/21/30	CI

Chart Lifecome Biochemistry Co.,Ltd.

Duration

Period

More charts

Company Profile

LIFECOME BIOCHEMISTRY CO LTD is a China-based company principally engaged in the development, production and sales of veterinary drugs. The Company's businesses include the production and sales of veterinary premixes, veterinary raw materials, veterinary soluble powders, food additives, feed additives and biological pesticide. Its products include bacitracin products, colistin sulfate products, flavomycin products, natamycin, Bacillus subtilis, Bacillus licheniformis, mixed probiotics, Bacillus thuringiensis series and Jinggangmycin series. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

02/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Veterinary Drugs

	1st Jan change	Capi.
LIFECOME BIOCHEMISTRY CO.,LTD.	-29.77%	320M
ZOETIS INC.	-11.29%	80.23B
BLUESTAR ADISSEO COMPANY	+24.38%	3.68B
VIRBAC	+3.06%	3.27B
VIMIAN GROUP AB	+12.67%	1.67B
VETOQUINOL SA	-2.64%	1.28B
JINYU BIO-TECHNOLOGY CO., LTD.	-26.65%	1.22B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-28.50%	1.19B
WUHAN KEQIAN BIOLOGY CO.,LTD	-19.43%	1.05B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-9.88%	943M